Follow-up Assessment of Change in Soil-transmitted Helminths Infection Intensity in Uganda (FACEIT-FU)
Change in Soil-transmitted Helminth Infection Intensity Following Mass Drug Administration With Ivermectin Plus Albendazole or Albendazole Alone in Ugandan Schoolchildren: a Follow-up Study to Assess Potential Drug Resistance
The goal of this prospective follow-up study nested within an open-label randomized controlled trial is to investigate the unexpectedly high prevalence of Ascaris lumbricoides infection observed 3-4 months after school-based mass drug administration with ivermectin plus albendazole (IVM-ALB) or albendazole alone (ALB) in Kisoro District, South-Western Uganda. By assessing initial treatment response and subsequent infection dynamics, the study will help clarify whether reduced drug efficacy, suboptimal treatment coverage, reinfection, or a combination of these factors may explain the previous findings.
The main questions the study aims to answer are:
- How effective are IVM-ALB and ALB against A. lumbricoides at 3 weeks, based on egg reduction and cure rates?
- How often do A. lumbricoides and other soil-transmitted helminth infections recur by 3 months?
- How effective are the treatments against Trichuris trichiura and hookworm?
- What can genetic characterization of Ascaris eggs reveal about parasite populations and potential drug resistance markers?
The study will enrol 450 pupils aged 5-14 years from three primary schools, which participated in the previous mass drug administration evaluation. In each school, 150 pupils will be randomly assigned equally to receive a single oral dose of:
- ivermectin (200 µg/kg) plus albendazole (400 mg); or
- albendazole (400 mg) alone.
Each treatment arm will include 225 pupils overall. Children will be included regardless of baseline infection status, following parental/guardian informed consent and child assent. Other pupils will receive routine albendazole under national deworming guidelines.
Stool samples will be collected before treatment and at 3 weeks and 3 months. Duplicate Kato-Katz thick smears will quantify A. lumbricoides, T. trichiura and hookworm eggs. The primary outcome is the arithmetic mean egg reduction rate for A. lumbricoides at 3 weeks. Secondary outcomes include cure rates at 3 weeks, reinfection rates at 3 months, egg reduction and cure rates for T. trichiura and hookworm, and genetic characterization of Ascaris populations and potential resistance markers. Adverse events will be recorded through passive safety monitoring.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Jennifer Keiser, Prof.
- Phone Number: +41 61 284 82 18
- Email: jennifer.keiser@swisstph.ch
Study Contact Backup
- Name: Peter Steinmann, Dr.
- Phone Number: +41 61 284 82 29
- Email: peter.steinmann@swisstph.ch
Study Locations
-
-
-
Kampala, Uganda
- Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health
-
Contact:
- Prudence Beinamaryo, Dr.
- Phone Number: +256-789-548-930
- Email: prudenceb13@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent provided by parent/guardian and assent provided by pupil
- School-aged children (5-14 years) enrolled in the respective study schools
- Able and willing to provide a stool sample before and 3 weeks and 3 months post-treatment
Exclusion Criteria:
- Presence or signs of major systemic illness
- Recent use of anthelmintic drugs in the 4 weeks before treatment
- Known allergy to study medication (i.e. benzimidazoles or ivermectin)
- Participation in other clinical trials
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: IVM (200 µg/kg) + ALB (400 mg)
A single tablet of albendazole (400mg) plus 200 µg/kg of ivermectin, provided as single oral dose. |
Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
Other Names:
World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.
Other Names:
|
|
Active Comparator: ALB (400mg)
A single tablet of albendazole (400mg), provided as single oral dose. |
Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Egg Reduction Rates (ERRs) for A. lumbricoides infection at 3 weeks post-treatment
Time Frame: 3 weeks after treatment
|
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the duplicate Kato-Katz thick smears and multiplying this number by a factor of twelve. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment. Egg reduction for A. lumbricoides infection will then be calculated as change in egg counts from baseline to 3 weeks post-treatment. |
3 weeks after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants A. lumbricoides egg negative at 3 weeks post-treatment (cured)
Time Frame: 3 weeks after treatment
|
The conversion from being egg positive pre-treatment to egg negative post-treatment, or cure rate (CR). |
3 weeks after treatment
|
|
Number of participants egg negative at 3 weeks with soil-transmitted helminth infections 3 months post-treatment (reinfected)
Time Frame: 3 months after treatment
|
Number of participants that converted from egg negative with Ascaris lumbricoides, Trichuris trichiura and/or hookworm infections at 3 weeks post-treatment to egg positive after 3 months. |
3 months after treatment
|
|
Number of participants with concomitant soil-transmitted helminth infections egg negative at 3 weeks post-treatment (cured)
Time Frame: 3 weeks after treatment
|
Number of participants that converted from egg positive with Trichuris trichiura and/or hookworm infections to egg negative after 3 weeks. |
3 weeks after treatment
|
|
Egg-reduction Rates (ERRs) against concomitant soil-transmitted helminth infections
Time Frame: 3 weeks after treatment
|
Percent change in arithmetic and geometric mean eggs per gram of stool from before to after treatment. ERRs will be calculated for Trichuris trichiura and hookworm infections as described in outcome 1. |
3 weeks after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jennifer Keiser, Prof., Swiss Tropical & Public Health Institute
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Parasitic Diseases
- Secernentea Infections
- Nematode Infections
- Helminthiasis
- Ascaridida Infections
- Ascariasis
- Organic Chemicals
- Heterocyclic Compounds
- Benzimidazoles
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Acids, Acyclic
- Carboxylic Acids
- Macrolides
- Lactones
- Polyketides
- Carbamates
- Ivermectin
- Albendazole
Other Study ID Numbers
Other Study ID Numbers
- 2283FU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
There is a data sharing agreement between Swiss TPH and Uganda MoH in place. Data may be shared with other researchers upon request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.